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CRISPR-SONIC: targeted somatic oncogene
knock-in enables rapid in vivo cancer
modeling
Haiwei Mou1†, Deniz M. Ozata1†, Jordan L. Smith1†, Ankur Sheel1, Suet-Yan Kwan1, Soren Hough2, Alper Kucukural1,
Zachary Kennedy1, Yueying Cao1 and Wen Xue1,3*
Abstract
CRISPR/Cas9 has revolutionized cancer mouse models. Although loss-of-function genetics by CRISPR/Cas9 is well-
established, generating gain-of-function alleles in somatic cancer models is still challenging because of the low
efficiency of gene knock-in. Here we developed CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling
(CRISPR-SONIC), a method for rapid in vivo cancer modeling using homology-independent repair to integrate
oncogenes at a targeted genomic locus. Using a dual guide RNA strategy, we integrated a plasmid donor in the
3′-UTR of mouse β-actin, allowing co-expression of reporter genes or oncogenes from the β-actin promoter. We
showed that knock-in of oncogenic Ras and loss of p53 efficiently induced intrahepatic cholangiocarcinoma in
mice. Further, our strategy can generate bioluminescent liver cancer to facilitate tumor imaging. This method
simplifies in vivo gain-of-function genetics by facilitating targeted integration of oncogenes.
Keywords: CRISPR, Liver cancer, Mouse model, Oncogene, RAS
Background
Genome editing has been revolutionized by the CRISPR/
Cas9 system [1]. CRISPR/Cas9 introduces double-strand
breaks (DSBs) at a target genomic locus through an eas-
ily programmable single guide RNA and the Cas9 en-
zyme. CRISPR/Cas9-mediated DSBs typically trigger one
of two major pathways for DNA repair: (1) homology-in-
dependent repair, such as non-homologous end recom-
bination (NHEJ), or (2) homology-directed repair (HDR)
with an endogenous or exogenous homologous DNA
template [1, 2]. Homology-independent pathways, i.e.,
NHEJ, have been widely used for disruption of genes by
inducing either frame shifts or premature stop codons,
while HDR is frequently used to precisely edit genes or
insert large sequences. However, the utility of HDR for
in vivo gene knock-in has been limited by the relatively
low editing efficiency of HDR compared to that of the
NHEJ pathway [3].
Previously, we and others showed CRISPR/Cas9 could
be employed to generate loss-of-function mutations in
tumor suppressor genes, making in vivo cancer studies
more efficient [4–11]. Gain-of-function alleles can also be
made by CRISPR/Cas9 and HDR donor [5, 12, 13]. How-
ever, the low efficiency of HDR-based gene knock-in pre-
sents a significant hurdle for researchers aiming to model
in vivo gain-of-function mutations in oncogenes.
While the overall cancer death rate continues to de-
cline, cancer is still the number two cause of death na-
tionally, in part, due to our limited understanding of the
underlying biology of many cancer types. New methods
of rapid in vivo modeling are needed to understand can-
cer biology. Liver cancer is a major cancer type with
poor prognosis [14, 15]. Specifically, liver cancer inci-
dence in the USA has tripled in the last 40 years, and
liver cancer deaths have been increasing since 2000 [16].
Transposon-mediated integration utilizing sleeping
beauty system is an established way to study multiple
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gain of function of oncogenes in the liver [17–19]. Al-
though transposons are powerful genetic tools, it is diffi-
cult to control the integration site and copy number.
Thus, a rapid and precise method allowing a greater de-
gree of targeted somatic oncogene knock-in is needed
for liver cancer.
Recent studies have demonstrated that
homology-independent pathways can be utilized to in-
sert large sequences in vivo [20–22]. Two guide RNAs
make knock-in feasible: one guide RNA targets the gen-
omic insertion locus, and the other linearizes the
non-homologous plasmid template containing the de-
sired sequence for integration. A similar strategy using
28 bp microhomology arms has also been reported [23].
Here we developed CRISPR-based Somatic Oncogene
kNock In for Cancer Modeling (CRISPR-SONIC), a
method for rapid in vivo cancer modeling. To first valid-
ate our approach, we started with the in vitro integration
of a GFP reporter sequence into the 3′-UTR of β-actin.
We confirmed this integration by analyzing and sequen-
cing genomic PCR amplicons and by assessing GFP ex-
pression driven by the endogenous mouse β-actin
promoter through flow cytometry. Next, we used hydro-
dynamic injection to deliver the CRISPR-SONIC system
to somatic hepatocytes and found targeted genomic inte-
gration of both GFP reporter and oncogenes such as
HRASG12V or KrasG12D. Both integrated HRASG12V and
KrasG12D are functional in vivo, demonstrated by rapid
induction of intrahepatic cholangiocarcinoma (ICC) in
mice [24]. Moreover, we further showed our strategy
could be used to generate bioluminescent in vivo cancer
models.
Methods
CRISPR vector
Guide RNAs targeting Actb and p53 were cloned into
the pX330 (Addgene 42230) vectors using standard pro-
tocols and primers (Additional file 1: Table S1 and S2)
[25]. The sgA guide targeting the donor plasmid
(Addgene, 83807) and IRES-GFP donor were purchased
from Addgene (Addgene, 83575). IRES-HRASG12V was
cloned into Addgene 83575. IRES-KrasG12D-IRES-GFP
and IRES-KrasG12D-IRES-luciferase were Gibson cloned
into Addgene 83575.
Cell culture
The Neuro2a cell line is from the University of Massa-
chusetts Medical School Cell line Freezer program ori-
ginally sourced from ATCC. The 293 fs, GreenGo, and
KP cells are from Dr. Tyler Jacks. Cells were cultured in
Dulbecco’s modification of Eagle’s medium (DMEM)
(Corning 10-013CV) with 10% serum (vol/vol) and 1%
penicillin/streptomycin (vol/vol) under standard cell cul-
ture conditions, 37C in 5% CO2 tissue culture incubator.
Transfection
Neuro2A and GreenGo cells were cultured in 6-well
plate at 30% confluency for transfection. Lipofectamine
3000 (Invitrogen, L3000015) was used for GreenGo cell
transfection, and Lipofectamine 2000 (Invitrogen,
11668027) was used for Neuro2A cell transfection ac-
cording to the manufacturer’s instructions. A total of
2-μg DNA was transfected per well (i.e., 0.66 μg sgA,
0.66 μg SgActin-Cas9, 0.66 μg Donor). Cells were col-
lected for either flow cytometry or genomic DNA isola-
tion 5 days post-transfection.
Transduction and infection
The 293 fs cells were plated at 40% confluency in 6-well
plates 1 day prior to transduction. The 293 fs cells were
transfected for lentiviral production with 600 ng
sgActin-3′-UTR_1, sgActin3′-UTR_2, sgNon-targeting,
or sgSf3b3 with packaging plasmids [26]. KP cells,
KrasG12D;p53−/− mouse lung cancer cells [26], were in-
fected with lentivirus (+ 2.5 μg/ml polybrene) and se-
lected with 1.5 μg/ml puromycin.
Cell viability assay
Two thousand cells post-selection were seeded in
black-wall clear bottom 96-well plates in 12 wells per
sample. Seventy-two hours after plating, cell viability
was assessed using Promega Cell Titer Glo Luminescent
Viability Assay (G7570) as per the manufacturer’s in-
structions. Luminescence at an integration time of 1 s
was measured on a plate reader.
Colony formation
Two thousand cells postselection were seeded in 6-well
plates and incubated for 10 days. After 10 days, cells
were first fixed with 4% formalin and then stained with
0.5% crystal violet solution. Plates were imaged with a
Nikon scanner.
Immunoblot
Whole cell extracts were lysed in RIPA buffer treated
with 1:100 Halt phosphatase cocktail inhibitor (Thermo
Fisher 78,420) and 1:50 Roche Complete protease inhibi-
tor (11836145001). Lysates were boiled for 5 min at 95C
with Nupage 4X Sample buffer (Invitrogen NP0007).
Equal amounts of protein from whole cell extracts were
separated on a 4–12% Bis Tris gel and transferred to a
nitrocellulose membrane and blocked with Odyssey
Blocking buffer. Blots were probed with primary anti-
bodies B-actin 1:1000 (CST 4970), Gapdh 1:1000 (EMD
MAB274), Hras 1:500 (Millipore OP23), and GFP 1:2000
(CST 2956) overnight at 4C. Blots were then incubated
with a fluorescent secondary antibody (LICOR) and im-
aged on the Odyssey Imaging Platform.
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Genomic DNA purification and PCR
Genomic DNA was purified from cells using the Roche
Genomic DNA purification kit (Cat no. 11796828001) at
least 5 days post-transfection. One hundred-nanogram
genomic DNA were used as template for sgActin inte-
gration PCR, and 300 ng genomic DNA was used as a
template for sgp53 integration. LA-Taq (Clontech) or
Herculase II (Agilent) was used for PCR.
TOPO cloning
PCR amplicons were first gel extracted using Qiagen QIA-
quick Gel Extraction kit (28704) as per the manufacturer’s
instructions. Gel-purified PCR fragments were then
TOPO cloned using the Zero Blunt TOPO PCR cloning
kit (K2835) for sequencing. TOPO clones were mini-
prepped using the Qiagen Spin Miniprep kit (272014),
and Sanger sequencing was performed by Genewiz.
Flow cytometry
Cells were transfected with lipofectamine 3000 as de-
scribed above. Five days after transfection, cells were
trypsinized, washed, and re-suspended in 500 μL PBS
and loaded to flow cytometry (BD, Accuri™ C6) for de-
tection of GFP-positive cells. Twenty thousand events
were collected for each sample. Samples were analyzed
and gated for dead cells and singlets using Flow Jo
Software.
Hydrodynamic tail vein injection
All plasmids used for the in vivo study were purified by
Qiagen Maxi-Prep Endotoxin-free Kit (Qiagen, 12,362)
according to the manufacturer’s instructions. Fifteen mi-
crograms per plasmid per mouse was mixed together in
2 ml 0.9% sterile saline at room temperature. Plasmids
were then delivered to mice by hydrodynamic tail vein
injection. Specifically, within 5–7 s, all 2 ml mixed plas-
mids were continuously and smoothly injected [19].
Mice were then warmed by heat lamp for 30 min to re-
cover from injection shock.
Histology and immunohistochemistry
Mouse liver tissue was collected from sacrificed mice, fixed
with 4% formalin overnight followed by dehydration for 24
+ hours in 70% ethanol. Tissues were then embedded in
paraffin by the UMassMed Morphology Core. H&E stain-
ing was performed by the Morphology Core according to
common methods on 4-μm paraffin sections. Immunohis-
tochemistry staining was performed following standard
protocols. Briefly, tumor sections were deparaffinized with
xylene and dehydrated with serial ethanol dilutions. Slides
were then boiled for 9min with 1mM citrate buffer (pH
6.0) for antigen retrieval. Next, 3% hydrogen peroxide was
used to inactivate endogenous peroxidase activities for 10
min at room temperature. Tissues were then blocked with
5% normal horse serum from ImmPRESS™ HRP
Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit (Vec-
tor labs, MP-7401-50) for 1 h at room temperature. Slides
were then incubated with primary antibody against Ck19
1:200 (Abcam, 133,496) or GFP 1:200 (CST, 2956) over-
night at 4 °C. Secondary HRP anti-rabbit antibody (Vector
labs, MP-7401-50) was incubated with sections for 1 h at
room temperature, followed by incubation with substrate/
chromogen (Fisher Scientific, TA-125-QHDX). Slides were
then counterstained with hematoxylin, dehydrated in etha-
nol, followed by a xylene wash and sealed with a coverslip
for long-term storage. H&E or IHC images were captured
using a Leica DMi8 microscope. IHC slides were quantified
by selection of five random fields per paraffin embedded
section, and positive hepatocytes per 20X field counted.
IVIS imaging
At the indicated time post injection, mice were given 200 μl
luciferin (15mg/ml) intraperitoneally. Signal was allowed to
stabilize for 10min and then loaded into the Perkin Elmer
IVIS machine for capture of luminescent signal (1min
exposure).
Results
CRISPR-SONIC-mediated homology-independent IRES-GFP
integration in mouse cells
Although CRISPR/Cas9 can facilitate the integration of
large DNA sequences into a target locus and is applicable
for human cells [20–22], a flexible in vivo gene knock-in
method has not been established for cancer mouse
models. To knock-in desired sequences, we chose the
β-actin locus because it is robustly expressed in most
mouse cell types and organs [27]. We first designed a
guide RNA targeting the 3′-UTR of β-actin locus. We also
adopted a published donor plasmid containing IRES (In-
ternal Ribosome Entry Site) sequence to express gene of
interest (GOI) and an sgRNA (named sgA) to linearize the
circular plasmid donor [21]. We then designed a strategy
to flexibly clone any GOI sequence into the donor plasmid
(Additional file 1: Figure S1). In this CRISPR-SONIC sys-
tem, knock-in occurs in three steps: (1) Cas9 and sgActin
cuts the 3′-UTR of β-actin; (2) Cas9 and sgA linearizes
the donor plasmid; (3) linearized donor is inserted in the
3′-UTR of β-actin through NHEJ. If insertion occurs in
the correct orientation, expression of the GOI will be
driven by the endogenous β-actin promoter and the IRES
signal respectively (Fig. 1a). Finally, the poly A signal en-
sures transcription termination after the GOI.
We then transfected combinations of two guide RNAs/
Cas9 and the plasmid GFP donor into the Neuro2A
mouse neuroblastoma cell line and analyzed integration
by flow cytometry five days post-transfection (Fig. 1b).
FACS analysis detected 15.3 ± 5.3% GFP-positive cells
post-transfection (Fig. 1c). Control transfections, GFP
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donor alone, GFP donor + sgActin/Cas9, and GFP donor +
sgA + Cas9 all produced a low percentage level of GFP by
flow cytometry 5 days after transfection (Fig. 1b, c). We
confirmed successful GFP donor integration in the Neu-
ro2a genome by PCR amplifying the fused GFP donor/
β-actin DNA sequence and Sanger sequencing the ampli-
con (Fig. 1d and Additional file 1: Table S3). To evaluate
CRISPR-SONIC efficiency in other cell lines, we performed
the same transfection in GreenGo cells and observed low
integration efficiency (~ 1%) likely due to a single nucleo-
tide polymorphism (SNP) two nucleotides adjacent to the
SgActin PAM sequence reducing CRISPR cutting (Add-
itional file 1: Figure S2).
As described above, CRISPR-SONIC occurs in three steps
with sgA linearizing the circular donor plasmid prior to its
insertion in the 3′-UTR of β-actin. Next, we tested whether
a linear DNA donor could alternatively be used for
CRISPR-SONIC. To generate a linear donor, we PCR amp-
lified and gel purified the IRES-GFP donor sequence. We
then tested whether our IRES-GFP amplicon could be
transfected with sgActin/Cas9 for efficient integration into
the 3′-UTR of β-actin. Using Neuro2a cells, we found that
approximately 6% of cells were GFP-positive 5 days
post-transfection with linear donor, compared to ap-
proximately 19% of cells transfected with circular
GFP donor, sgA, and Sg-Actin/Cas9 (Additional file 1:
Figure S3). Interestingly, co-injection of PCR donor
plus sgActin/Cas9 by hydrodynamic injection did not
generate GFP-positive cells in mouse liver (data not
shown). It is possible that the linear PCR product is
not stable in vivo or unable to efficiently translocate
into the nucleus. More investigation will be required
to understand variances in integration efficiency be-
tween circular and linear donor plasmids.
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Fig. 1 CRISPR-SONIC enables homology-independent IRES-GFP integration in mouse cells. a Schematic showing the target genomic locus, guide
RNAs, and donor plasmid. b Neuro2A cells were transfected with indicated plasmids. Five days post-transfection, cells were trypsinized, washed
with PBS, re-suspended in PBS, and analyzed by flow cytometry for detection of GFP-positive cells. c Statistical analysis of percentage of GFP-
positive cells. Reported as mean percentage. Error bars are s.d. (n = 3). d PCR detecting genomic integration and representative sanger
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Efficient and targeted homology-independent integration
of IRES GFP in mouse liver
Following in vitro validation of our editing strategy, we
then tested our strategy in vivo. We used hydro-
dynamic tail-vein injection to deliver CRISPR-SONIC
to mouse hepatocytes [17–19]. We again used sgAc-
tin/Cas9, sgA, and the GFP donor plasmids for tar-
geted integration (Fig. 2a). Seven days after
hydrodynamic injection, mice (n = 3) were sacrificed
for liver tissue collection. By immunohistochemistry
(IHC) staining, we detected 12.0 ± 2.3% GFP-positive
hepatocytes in vivo (p < 0.05 compared to control
group) (Fig. 2b, c). Next, we confirmed IRES-GFP se-
quence integration at the target locus through PCR
detection of the expected band and subsequent
Sanger sequencing of the amplicon (Fig. 2d).
Development of intrahepatic cholangiocarcinoma
following CRISPR-SONIC of oncogenic HRASG12V
ICC is an aggressive cancer type lacking effective therapy
[28]. TP53 (26–44% of cases), and KRAS (16–18%) are
top driver mutations in ICC [29, 30]. Previous studies
showed that oncogenic HRAS or KRAS can cooperate
with p53 loss to drive ICC in mouse models using
Cre-LoxP or transposons [24, 31]. To determine whether
we could apply CRISPR-SONIC to knock-in oncogenic
Ras such as HRASG12V to model ICC in vivo, we cloned
a HRASG12V donor plasmid with human HRAS sequence
(Fig. 3a) [32]. First, we validated the HRAS donor plas-
mid in vitro. Five days post-transfection of the
CRISPR-SONIC plasmids in Neuro2A cells, we detected
HRAS over-expression by western blot using GFP donor
as a control (Fig. 3b). Next, hydrodynamic injection was
used to deliver the CRISPR-SONIC components to a
mouse strain with p53 liver knockout (p53fl/fl; Alb-cre/
+) (Fig. 3a) [33, 34]. One month post-injection, we ob-
served gross tumor formation in the livers, 8.0 ± 4.0 tu-
mors per mouse (Fig. 3c, d). As a control, mice injected
with sgActin/Cas9, sgA, and GFP donor did not develop
liver tumors (Fig. 3d, p < 0.05). To confirm that
HRASG12V was integrated into the β-actin locus, we de-
tected the expected PCR bands and Sanger sequenced
the bands (Fig. 3e).
To characterize the genotype at integration sites, we
gel purified the integrated amplicons generated by P1,P2
and P3,P4 primer sets and screened 15+ TOPO clones
per group (Additional file 1: Figure S4A and B). Using
primer set P1-P2 through the Actin-HRAS fused
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Fig. 2 CRISPR-SONIC enables efficient IRES-GFP integration in vivo. a Schematic showing the target genomic locus, guide RNAs, and donor
plasmid for in vivo integration. Hydrodynamic tail vein injection was performed to deliver the plasmids to FVB mice. Seven days later, mouse
livers were collected for histological analysis or genomic DNA purification. b IHC was performed to examine the GFP-positive cells from liver
slides. Scale bars are 25 μm. c Statistical analysis of IHC GFP-positive cells from three mice. Error bars are s.d. (n = 1 for PBS and n = 3 mice for GFP
donor). d Genomic PCR detected integration bands. The last two lanes are biological replicate samples
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sequence, we did not detect indels in 15/17 clones. In 2
clones, the same complex indel was detected by Sanger
sequencing (ATCCTCTTCT) (Additional file 1: Figure
S4C and D and Additional files 2 and 3). Using primer
set P3-P4 to characterize the Actin-IRES fused se-
quences, we Sanger sequenced 15 TOPO clones and did
not detect any indels (Additional file 1: Figure S4).
Finally, to better characterize the tumors, we collected
tumor tissue for histologic analyses. Using IHC, we ob-
served that tumors are positive for the primary ICC
marker, cytokeratin 19 (Ck19) (Fig. 3f ) [35–38].
CRISPR-SONIC enables combinatorial KrasG12D knock-in
and p53 knockout in immunocompetent mice
To test whether the use of CRISPR-SONIC could be
broadly used to model cancer driven by different onco-
genes, we cloned another oncogenic Ras, KrasG12D, into
our donor plasmid. ICC driven by KrasG12D also requires
loss of function in p53 [24]. To track KrasG12D integra-
tion and expression, we included an IRES-GFP cassette
after Kras that would make the resulting tumors GFP
positive (Fig. 4a). This dual IRES donor (IRES- KrasG12-
D-IRES-GFP) generated a similar level and percentage of
GFP-positive cells compared to the single IRES GFP
donor in cells Additional file 1: Figure S5).
Next, we co-injected CRISPR-SONIC plasmids (Kras-
donor, sgActin/Cas9, and sgA) with a guide RNA target-
ing p53 (sgp53) [6] to knockout p53 in hepatocytes of
wildtype B6 mice (termed “+sgActin group” in Fig. 4a).
One month post-hydrodynamic injection, we sacrificed
this cohort of mice (n = 5) and observed liver tumor for-
mation (Fig. 4b). IHC staining revealed GFP-positive and
Ck19-positive tumor cells with abundant stroma, a
known feature of ICC [35] (Fig. 4c). Concordantly,
CRISPR-SONIC also generated liver tumors (n = 3) in
wildtype FVB mice (Additional file 1: Figure S6).
To characterize the possibility of the donor integrating
into and expressing from the sgp53 target site, we per-
formed control hydrodynamic injection using
Kras-donor+ sgA+sgp53/Cas9 (termed “-sgActin group”
in Fig. 4) (n = 5 mice). At 1 month, we did not observe
tumor formation, nor did we detect GFP-positive cells
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by IHC staining (Fig. 4). However, when we performed
PCR in liver genomic DNA, we did detect integration of
the donor at the p53 locus despite the lack of tumori-
genesis or detectable GFP at the assayed time point
(Additional file 1: Figure S7). In Neuro2A cells, the
KrasG12D-IRES-GFP with Cas9, sgA, and sgp53 did not
generate strong GFP expression (Additional file 1: Figure
S5), indicative of limited expression of our donor from
the p53 locus. Together, these data suggest that
CRISPR-SONIC requires relatively strong endogenous
promoters to drive successful expression of the inte-
grated donor or oncogene.
Generation of bioluminescent tumors using CRISPR-SONIC
Bioluminescent labeling of tumors enables researchers
to monitor tumor initiation and progression in live ani-
mals over time. Real-time analysis in live animals pro-
vides clear advantages for understanding dynamics of
tumor growth. We engineered a donor plasmid contain-
ing an IRES-luciferase sequence after oncogenic
KrasG12D and injected mice using the same in vivo inte-
gration strategy (Fig. 5a). Five weeks following hydro-
dynamic injection, we used in vivo bioluminescent
imaging to quantify tumor formation over time and ob-
served positive signal indicative of tumorigenesis
(Fig. 5b). Weekly imaging allowed for measurement and
tracking of tumor growth over time (Fig. 5c). Following
live imaging, downstream H&E and IHC staining of
Ck19 confirmed ICC formation (Fig. 5d). These data
suggest that our method facilitates one-step oncogene
and reporter knock-in to facilitate live tumor imaging.
Discussion
Herein we reported a flexible system for targeted som-
atic oncogene knock-in to facilitate in vivo cancer mod-
eling. This method enables rapid knock-in of
gain-of-function oncogenes and reporter genes in mice.
CRISPR-SONIC enables efficient homology-independent
DNA integration in vivo
Previous somatic integration strategies for cancer model-
ing, i.e., point mutations or gene knock-in, relied on
low-efficiency HDR, limiting the ease of its application
both in vitro and in vivo [12, 39]. To satisfy the need for
rapid and efficient modeling of cancer in vivo, we turned
to CRISPR/Cas9 homology-independent targeted inte-
gration. While homology-independent pathways, i.e.,
NHEJ, are typically more efficient, they are also more
error-prone and therefore more frequently utilized for
gene disruption rather than DNA integration. To
B
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combat this limitation, we adopted a donor with an IRES
sequence before the coding region of our gene of inter-
est [21]. Compared to a microhomology-mediated
end-joining (MMEJ) strategy to knock in 2A-GFP at
Actin [23], small indel mutations before IRES do not
affect translation of the gene of interest in our system.
We used the same strategy in vivo and found similarly
high efficiency of GFP integration at the target locus.
Our IHC staining indicated approximately ~ 10% of the
hepatocytes were GFP positive (Fig. 2). This is a signifi-
cant improvement compared to a 0.5% HDR knock-in
efficiency we previously reported using hydrodynamic
injection of an HDR donor [5].
CRISPR-SONIC enables in vivo modeling of ICC
We tested our strategy using Ras isoforms, but presum-
ably any desired oncogenic DNA sequence could be
used and tailored to the cancer type of interest. We first
chose the well-characterized oncogenic HRASG12V mu-
tant as a donor and used p53fl/fl;Alb-cre/+ mice which
harbor p53 knockout mutations in the liver. As ex-
pected, we observed tumor formation after
CRISPR-SONIC-mediated HRASG12V integration (Fig. 3).
We then used an oncogenic KrasG12D as a donor and de-
livered this to wildtype B6 or FVB mice along with a
guide RNA targeting p53. As expected, CRISPR-SONIC
delivery of mutant Kras cooperated with sgp53 to induce
ICC in vivo (Fig. 4).
Next, we expanded our CRISPR-SONIC system to in-
clude knock-in of a bioluminescent marker to enable
researchers to follow tumor initiation and maintenance
in real time. Integrating this luciferase donor allowed us
to dynamically quantify tumor size in our model of ICC
(Fig. 5).
Caveats and solutions
CRISPR-SONIC provides a targeted and higher effi-
ciency knock-in for cancer modeling; however, several
caveats need to be considered when applying the tech-
nology. First, while CRISPR-SONIC offers a higher de-
gree of genomic targeting than the random genetic
insertions associated with transposon delivery, the
CRISPR-SONIC system can result in off-target inser-
tions. The donor may insert at off-target sites of the as-
sociated sgRNAs or the DSBs that naturally occur in
cells [40]. To mitigate the off-target effects of the
CRISPR-SONIC system, screening sgRNAs with minimal
off-target effects may help to reduce integration at
CRISPR off-target sites; although, the donor may still in-
tegrate at the DSBs that naturally occur in cells. When
the CRISPR-SONIC system (SgA, sgActin, Donor) is
co-delivered with a sgRNA targeting a tumor suppressor
(i.e., p53) for generation of tumor, CRISPR-SONIC can
integrate at both sgRNA sites, sgActin and sgp53. Not-
ably delivery of SgA, sgp53, and donor did not produce
either GFP-positive expression in vitro or result in
tumor formation in vivo. However, by genomic PCR, we
did detect in vivo integration of the donor plasmid at
the sgp53 site despite the lack of tumor formation (Fig. 4
and Additional file 1: Figure S7). Future studies are
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Fig. 5 CRISPR/Cas9 enables generation of bioluminescent liver tumors. a Schematic showing the target genomic locus, guide RNAs, and donor
plasmid. Hydrodynamic tail vein injection was performed to deliver the CRISPR/Cas9 system to FVB mice. b, c IVIS imaging was performed weekly.
d H&E and Ck19 IHC staining of liver tumors. Dashed lines denote tumor/liver border. Scale bars are 25 μm
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required to determine the degree of off-target donor
insertion.
The second major caveat is that the donor vector can
be integrated in both orientations [22]. As expected, we
also detected inverted integration in the total liver DNA
(Additional file 1: Figure S6D). Users should note that
CRISPR-SONIC cassettes inserted antisense to the pro-
moter will not be detected by GFP flow cytometry. Fur-
ther, cassettes inserted distal to a promoter will also go
undetected by flow cytometry. During our development
of CRISPR-SONIC, we focused on the phenotype driven
by the forward orientation of our donor. Future work
will determine whether the reverse orientation of the
inserted plasmid sequence has adverse effects in vivo. A
recently published HITI method used inverted sgRNA
sites flanking the GOI to reduce reverse insertion. Re-
verse insertion without indels will create an intact
sgRNA target sequence and will be subjected to add-
itional Cas9 cutting until forward insertion or indels
occur to eliminate sgRNA binding sites [22].
Third, the level of expression of the GOI must also be
considered when designing sgRNAs and donor plasmids
for CRISPR-SONIC. We chose to target the 3′-UTR of
the β-actin locus as the preferred target site for integra-
tion due to the strong promoter activity of mouse actin.
As such, it is possible that the RAS expression level in
our system is different from that of transposon RAS
[41]. When lower expression is desired, integration can
be engineered at the endogenous gene locus [12, 22].
An additional consideration when using the
CRISPR-SONIC system is that the Actin 3′-UTR may
have a role in regulating β-Actin expression or function.
Recent studies showed that Cas9 targeting can induce
long deletions which may affect beta-actin function and
subsequently cell viability [22, 42]. Of note, infecting KP
cells (KrasG12D p53−/− mouse lung cancer cells) with two
guides against the actin UTR does not result in reduced
expression of β-Actin or notably change cell morph-
ology; however, it does moderately reduce cell prolifera-
tion by viability and colony formation assays. The effect
is modest compared to an sgRNA targeting an essential
gene, Sf3b3. One possible explanation is that the
off-target effects of sgActinUTR contributed to the ef-
fects on cell viability (Additional file 1: Figure S8). Users
should exercise caution when selecting the on-target
locus for integration, and further, it is advisable to test
multiple guides against the on-target locus before
proceeding.
Finally, unlike transposon-based delivery, the
CRISPR-SONIC system does not allow for unlimited
multiplexing of gain-of-function alleles. Multiple trans-
posons expressing different transgenes can insert in the
genome of one hepatocyte [17, 43]. Thus, the transposon
delivery system better accommodates users wishing to
multiplex 2+ gain of function alleles. However; it should
be noted that CRISPR-SONIC could be employed for
multiplexing up to two insertions per diploid cell (i.e.,
two alleles of Actin 3′-UTRs per cell).
Conclusions
In conclusion, our method facilitates flexible oncogene
knock-in to rapidly model cancer in vivo. Further, while
we show CRISPR-SONIC delivery via hydrodynamic de-
livery in the liver, CRISPR-SONIC cancer modeling may
also potentially be applied to other tissues with delivery
by lentivirus or adeno-associated virus respectively. Fi-
nally, CRISPR-SONIC may also be applied to study other
genetic diseases including loss-of-function diseases, by
knocking-in of a rescue gene at a safe harbor genomic
locus.
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